Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
May 16, 2018
In re Novartis and Par Antitrust Litigation
Case Number:
1:18-cv-04361
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Baker & Hostetler
- Berger Montague
- Buchanan Ingersoll
- Cravath Swaine
- DiCello Levitt
- Dorsey & Whitney
- Duncan & Allen
- Faruqi & Faruqi
- Fine Kaplan
- Garwin Gerstein
- Gilbert LLP
- Grant & Eisenhofer
- Hangley Aronchick
- Hartley LLP
- Heim Payne
- Husch Blackwell
- Kenny Nachwalter
- Labaton Keller
- Lockridge Grindal
- Odom & Des Roches
- Rolnick Kramer
- Skadden Arps
- Smith Segura
- Tadler Law LLP
- Williams & Connolly
- Wilson Sonsini
Companies
- Cardinal Health Inc.
- Cencora Inc.
- CVS Health Corp.
- Endo International PLC
- Express Scripts Holding Co.
- Lupin Ltd.
- Mylan NV
- Novartis AG
- Par Pharmaceutical Cos. Inc.
- Rite Aid Corp.
- Rochester Drug Cooperative Inc.
- The Kroger Co.
- United Food & Commercial Workers International Union
Sectors & Industries:
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
July 26, 2023
Novartis Direct Buyers' Attys Get $42M In Drug Delay Case
A New York federal judge awarded counsel for direct purchasers of Novartis' hypertension medication $42.15 million in attorney fees, according to an order Tuesday granting final approval of a $126 million settlement resolving claims that Novartis had an illicit arrangement with Par Pharmaceuticals to delay the release of an Exforge generic.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login